Paul Tudor Jones Krystal Biotech, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$64.85 - $82.4 $748,758 - $951,390
11,546 New
11,546 $805,000
Q1 2022

May 16, 2022
SELL
$51.99 - $72.11 $653,098 - $905,845
-12,562 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$39.81 - $88.24 $500,093 - $1.11 Million
12,562 New
12,562 $879,000

Others Institutions Holding KRYS

# of Institutions
309
Shares Held
24.3M
Call Options Held
483K
Put Options Held
364K
View Full List

About Krystal Biotech, Inc.

KRYS Quotes by TradingView
  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.92B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email